Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.

Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, Füreder T, Rajky O, Berghoff AS, Preusser M, Heiduschka G.

Histopathology. 2018 May 9. doi: 10.1111/his.13646. [Epub ahead of print]

PMID:
29742291
2.

ÖGRO survey on radiotherapy capacity in Austria : Status quo and estimation of future demands.

Zurl B, Bayerl A, De Vries A, Geinitz H, Hawliczek R, Knocke-Abulesz TH, Lukas P, Pötter R, Raunik W, Scholz B, Schratter-Sehn A, Sedlmayer F, Seewald D, Selzer E, Kapp KS.

Strahlenther Onkol. 2018 Apr;194(4):284-292. doi: 10.1007/s00066-017-1240-8. Epub 2017 Dec 8.

PMID:
29222711
3.

P16 positivity and regression grade predict survival after neoadjuvant radiotherapy of OSCC.

Eder-Czembirek C, Sulzbacher I, Fuereder T, Selzer E.

Oral Dis. 2018 May;24(4):544-551. doi: 10.1111/odi.12814. Epub 2018 Mar 13.

PMID:
29215771
4.

The effect of adjuvant radiotherapy on radial forearm free flap volume after soft palate reconstruction in 13 patients.

Haymerle G, Enzenhofer E, Lechner W, Stock M, Schratter-Sehn A, Vyskocil E, Bachtiary B, Selzer E, Erovic BM.

Clin Otolaryngol. 2018 Apr;43(2):742-745. doi: 10.1111/coa.13042. Epub 2017 Dec 15. No abstract available.

PMID:
29194976
5.

A 5‑year update of patients with HPV positive versus negative oropharyngeal cancer after radiochemotherapy in Austria.

Lill C, Bachtiary B, Selzer E, Mittlboeck M, Thurnher D.

Wien Klin Wochenschr. 2017 Jun;129(11-12):398-403. doi: 10.1007/s00508-017-1171-5. Epub 2017 Feb 15.

6.

CENP-A Modifications on Ser68 and Lys124 Are Dispensable for Establishment, Maintenance, and Long-Term Function of Human Centromeres.

Fachinetti D, Logsdon GA, Abdullah A, Selzer EB, Cleveland DW, Black BE.

Dev Cell. 2017 Jan 9;40(1):104-113. doi: 10.1016/j.devcel.2016.12.014.

7.

Erratum to "Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival" [Oral Oncol. 60 (2016) 1-7].

Eder-Czembirek C, Czembirek C, Selzer E.

Oral Oncol. 2016 Dec;63:e8. doi: 10.1016/j.oraloncology.2016.10.016. Epub 2016 Oct 31. No abstract available.

PMID:
27810259
8.

Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.

Ahmed MA, Selzer E, Dörr W, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B.

Oncotarget. 2016 Oct 25;7(43):69976-69990. doi: 10.18632/oncotarget.12099.

9.

Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival.

Eder-Czembirek C, Czembirek C, Selzer E.

Oral Oncol. 2016 Sep;60:1-7. doi: 10.1016/j.oraloncology.2016.06.014. Epub 2016 Jun 28. Erratum in: Oral Oncol. 2016 Dec;63:e8.

PMID:
27531866
10.

Pre-therapeutic fibrinogen levels are of prognostic significance in locally advanced head and neck cancer.

Selzer E, Grah A, Heiduschka G, Kornek G, Thurnher D.

Wien Klin Wochenschr. 2016 May;128(9-10):320-8. doi: 10.1007/s00508-016-0963-3. Epub 2016 Feb 26.

PMID:
26919854
11.

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.

Grunt TW, Hebar A, Laffer S, Wagner R, Peter B, Herrmann H, Graf A, Bilban M, Posch M, Hoermann G, Mayerhofer M, Eisenwort G, Zielinski CC, Selzer E, Valent P.

Am J Cancer Res. 2015 Jan 15;5(2):560-74. eCollection 2015.

12.

Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems.

Selzer E, Grah A, Heiduschka G, Kornek G, Thurnher D.

Strahlenther Onkol. 2015 Jun;191(6):486-94. doi: 10.1007/s00066-014-0803-1. Epub 2015 Jan 13.

PMID:
25583136
13.

Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy.

Heiduschka G, Grah A, Oberndorfer F, Kadletz L, Altorjai G, Kornek G, Wrba F, Thurnher D, Selzer E.

Strahlenther Onkol. 2015 Mar;191(3):209-16. doi: 10.1007/s00066-014-0753-7. Epub 2014 Sep 25.

PMID:
25252603
14.

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.

Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.

PMID:
25188816
15.

Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab.

Heiduschka G, Grah A, Oberndorfer F, Seemann R, Kranz A, Kornek G, Wrba F, Thurnher D, Selzer E.

Strahlenther Onkol. 2014 Sep;190(9):832-8. doi: 10.1007/s00066-014-0652-y. Epub 2014 Apr 9.

PMID:
24715244
16.

Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments.

Selzer E, Kornek G.

Expert Rev Clin Pharmacol. 2013 Nov;6(6):663-76. doi: 10.1586/17512433.2013.841540. Review.

PMID:
24164614
17.

4-({(Z)-5-[(Z)-3-Eth-oxy-4-hy-droxy-benzyl-idene]-3-methyl-4-oxo-1,3-thia-zolidin-2-yl-idene}amino)-benzoic acid dimethyl-formamide monosolvate.

Kosma P, Selzer E, Mereiter K.

Acta Crystallogr Sect E Struct Rep Online. 2012 Dec 1;68(Pt 12):o3417-8. doi: 10.1107/S1600536812047307. Epub 2012 Nov 24.

18.

The impact of molecular targets in cancer drug development: major hurdles and future strategies.

Hebar A, Valent P, Selzer E.

Expert Rev Clin Pharmacol. 2013 Jan;6(1):23-34. doi: 10.1586/ecp.12.71.

PMID:
23272790
19.

NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.

Hebar A, Rütgen BC, Selzer E.

PLoS One. 2012;7(9):e45015. doi: 10.1371/journal.pone.0045015. Epub 2012 Sep 13.

20.

Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.

Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, Greil R, Bachtiary B, Tinchon C, Anderhuber W, Burian M, Kasparek AK, Elsäßer W, Kainz H, Riedl R, Kopp M, Kornek G.

Eur J Cancer. 2013 Jan;49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14.

PMID:
22981499
21.

Survival of patients with pathologic T0N+ oral and oropharyngeal cancer after neoadjuvant therapy and surgery: the minority report.

Perisanidis C, Sulzbacher I, Mittlböck M, Mitchell D, Czembirek C, Seemann R, Ewers R, Schopper C, Selzer E.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Mar;115(3):293-8. doi: 10.1016/j.oooo.2012.03.033. Epub 2012 Aug 30.

PMID:
22939322
22.

[Biological effect and tumor risk of diagnostic x-rays. The "war of the theories"].

Selzer E, Hebar A.

Radiologe. 2012 Oct;52(10):892-7. doi: 10.1007/s00117-012-2336-x. German.

PMID:
22914871
23.

HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer.

Perisanidis C, Savarese-Brenner B, Würger T, Wrba F, Huynh A, Schopper C, Kornek G, Selzer E, Ewers R, Psyrri A, Krainer M, Filipits M.

Oral Dis. 2013 Mar;19(2):206-11. doi: 10.1111/j.1601-0825.2012.01972.x. Epub 2012 Aug 14.

PMID:
22891969
24.

Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer.

Perisanidis C, Wrba F, Brandstetter A, Kornek G, Mitchell D, Seemann R, Selzer E, Ewers R, Filipits M.

Br J Oral Maxillofac Surg. 2013 Apr;51(3):234-40. doi: 10.1016/j.bjoms.2012.06.009. Epub 2012 Aug 11.

PMID:
22889668
25.

Postoperative failure of platelet recovery is an independent risk factor for poor survival in patients with oral and oropharyngeal cancer.

Perisanidis C, Mittlböck M, Schoppmann A, Kornek G, Starlinger P, Stift A, Selzer E, Schopper C, Ewers R.

Clin Oral Investig. 2013 Apr;17(3):913-9. doi: 10.1007/s00784-012-0755-8. Epub 2012 May 29.

PMID:
22643871
26.

Basic principles of molecular effects of irradiation.

Selzer E, Hebar A.

Wien Med Wochenschr. 2012 Feb;162(3-4):47-54. doi: 10.1007/s10354-012-0052-9. Review.

PMID:
22476592
27.

Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.

Vormittag L, Lemaire C, Radonjic D, Kornek G, Selzer E.

Strahlenther Onkol. 2012 Mar;188(3):235-42. doi: 10.1007/s00066-011-0040-9. Epub 2012 Feb 10.

PMID:
22318328
28.

Continuous thrombin infusion leads to a bleeding phenotype in sheep.

Siller-Matula JM, Miller I, Gemeiner M, Plasenzotti R, Bayer G, Mesteri I, Fabry A, Petroczi K, Nöbauer K, Razzazi-Fazeli E, Planchon S, Renaut J, Quehenberger P, Selzer E, Jilma B.

Thromb Res. 2012 Aug;130(2):226-36. doi: 10.1016/j.thromres.2011.09.019. Epub 2012 Jan 30.

PMID:
22289207
29.

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.

Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, Jäger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, Schwarzinger I, Sperr WR, Valent P.

Haematologica. 2012 Feb;97(2):219-26. doi: 10.3324/haematol.2010.035006. Epub 2011 Oct 11.

30.

Impact of elective neck dissection on regional recurrence and survival in cN0 staged oral maxillary squamous cell carcinoma.

Poeschl PW, Seemann R, Czembirek C, Russmueller G, Sulzbacher I, Selzer E, Nuhic D, Ewers R.

Oral Oncol. 2012 Feb;48(2):173-8. doi: 10.1016/j.oraloncology.2011.09.006. Epub 2011 Oct 4.

PMID:
21974917
31.

Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.

Selzer E, Liederer S, Lemaire C, Kren G, Radonjic D, Kornek G, Knocke T, Pötter R, Bachtiary B.

Strahlenther Onkol. 2011 Jun;187(6):373-7. doi: 10.1007/s00066-011-2217-7. Epub 2011 May 16.

PMID:
21603990
32.

Survival of patients with HPV-positive oropharyngeal cancer after radiochemotherapy is significantly enhanced.

Lill C, Kornek G, Bachtiary B, Selzer E, Schopper C, Mittlboeck M, Burian M, Wrba F, Thurnher D.

Wien Klin Wochenschr. 2011 Apr;123(7-8):215-21. doi: 10.1007/s00508-011-1553-z. Epub 2011 Mar 30.

PMID:
21448626
33.

Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies.

Weichselbaumer M, Willmann M, Reifinger M, Singer J, Bajna E, Sobanov Y, Mechtcherikova D, Selzer E, Thalhammer JG, Kammerer R, Jensen-Jarolim E.

Version 2. PLoS Curr. 2011 Mar 16 [revised 2011 Jan 1];3:RRN1223.

34.

Perceptions of U.S. physicians regarding the entry-level doctoral degree in physician assistant education.

Muma RD, Smith BS, Anderson N, Richardson M, Selzer E, White R.

J Allied Health. 2011 Spring;40(1):25-33. Review.

PMID:
21399849
35.

[Tumor stem cell research - basis and challenge for diagnosis and therapy].

Karlic H, Herrmann H, Schulenburg A, Grunt TW, Laffer S, Mirkina I, Hubmann R, Shehata M, Marian B, Selzer E, Pfeilstöcker M, Pittermann E, Jäger U, Pehamberger H, Zielinski C, Valent P.

Wien Klin Wochenschr. 2010 Jul;122(13-14):423-36. doi: 10.1007/s00508-010-1408-z. Epub 2010 Jul 22. Review. German.

PMID:
20645015
36.

Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines.

Eder-Czembirek C, Erovic BM, Czembirek C, Brunner M, Selzer E, Pötter R, Thurnher D.

Strahlenther Onkol. 2010 Mar;186(3):143-8. doi: 10.1007/s00066-010-2069-6. Epub 2010 Feb 22.

PMID:
20339825
37.

Impact of molecular targets in cancer drug development: historical influence and future perspectives.

Selzer E.

Expert Rev Clin Pharmacol. 2010 Mar;3(2):161-3. doi: 10.1586/ecp.10.8. No abstract available.

PMID:
22111562
38.

Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis.

Blüml S, Binder NB, Niederreiter B, Polzer K, Hayer S, Tauber S, Schett G, Scheinecker C, Kollias G, Selzer E, Bilban M, Smolen JS, Superti-Furga G, Redlich K.

Arthritis Rheum. 2010 Jun;62(6):1608-19. doi: 10.1002/art.27399.

39.

The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells.

Czembirek C, Eder-Czembirek C, Erovic BM, Turhani D, Spittler A, Selzer E, Pötter R, Thurnher D.

Strahlenther Onkol. 2009 May;185(5):310-7. doi: 10.1007/s00066-009-1929-4. Epub 2009 May 15.

PMID:
19440670
40.

Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound.

Willmann M, Wacheck V, Buckley J, Nagy K, Thalhammer J, Paschke R, Triche T, Jansen B, Selzer E.

Eur J Clin Invest. 2009 May;39(5):384-94. doi: 10.1111/j.1365-2362.2009.02105.x.

PMID:
19309323
41.

Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel.

Kornek G, Selzer E.

Curr Pharm Des. 2009;15(2):207-42. Review.

PMID:
19149613
42.

After injection into the striatum, in vitro-differentiated microglia- and bone marrow-derived dendritic cells can leave the central nervous system via the blood stream.

Hochmeister S, Zeitelhofer M, Bauer J, Nicolussi EM, Fischer MT, Heinke B, Selzer E, Lassmann H, Bradl M.

Am J Pathol. 2008 Dec;173(6):1669-81. doi: 10.2353/ajpath.2008.080234. Epub 2008 Oct 30.

43.

Murine mobilized peripheral blood stem cells have a lower capacity than bone marrow to induce mixed chimerism and tolerance.

Koporc Z, Pilat N, Nierlich P, Blaha P, Bigenzahn S, Pree I, Selzer E, Sykes M, Muehlbacher F, Wekerle T.

Am J Transplant. 2008 Oct;8(10):2025-36. doi: 10.1111/j.1600-6143.2008.02371.x.

44.

[Organ sparing treatment modalities - which type of treatment for which carcinoma?].

Kornek GV, Selzer E.

Wien Med Wochenschr. 2008;158(9-10):264-9. doi: 10.1007/s10354-008-0531-1. Review. German.

PMID:
18560952
45.

Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.

Skoda C, Erovic BM, Wachek V, Vormittag L, Wrba F, Martinek H, Heiduschka G, Kloimstein P, Selzer E, Thurnher D.

Oncol Rep. 2008 Jun;19(6):1499-503.

PMID:
18497956
46.

Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer.

Erovic BM, Woegerbauer M, Pammer J, Selzer E, Grasl MCh, Thurnher D.

Eur J Clin Invest. 2008 Jan;38(1):61-6. doi: 10.1111/j.1365-2362.2007.01896.x.

PMID:
18173552
47.

Validity of sentinel lymph node (SLN) detection following adjuvant radiochemotherapy (RCT) in head and neck squamous cell carcinoma (HNSCC).

Wagner A, Kermer C, Zettinig G, Lang S, Schicho K, Noebauer I, Kainberger F, Selzer E, Leitha T.

Technol Cancer Res Treat. 2007 Dec;6(6):655-60.

PMID:
17994797
48.

Transition from enhanced T cell infiltration to inflammation in the myelin-degenerative central nervous system.

Grundtner R, Dornmair K, Dahm R, Flügel A, Kawakami N, Zeitelhofer M, Schoderboeck L, Nosov M, Selzer E, Willheim M, Kiebler M, Wekerle H, Lassmann H, Bradl M.

Neurobiol Dis. 2007 Dec;28(3):261-75. Epub 2007 Aug 3.

PMID:
17889548
49.

Challenging a dogma--surgery yields superior long-term results for T1a squamous cell carcinoma of the glottic larynx compared to radiotherapy.

Thurnher D, Erovic BM, Frommlet F, Brannath W, Ehrenberger K, Jansen B, Selzer E, Grasl MC.

Eur J Surg Oncol. 2008 Jun;34(6):692-8. Epub 2007 Aug 8.

PMID:
17686606
50.

Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.

Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Schernthaner GH, Wacheck V, Selzer E, Sperr WR, Valent P.

Eur J Clin Invest. 2007 Jan;37(1):73-82.

PMID:
17181570

Supplemental Content

Loading ...
Support Center